

## ALAPIS SA (Company's Number in the Register of Societes Anonymes: 6013/ 8057/06/B/86/11) REGISTERED ADRESS: 2,AFTOKRATOROS NIKOLAOU STR, P.C 17671 ATHENS DATA AND INFORMATION FOR THE PERIOD 1 JANUARY 2009 TO 31 MARCH 2009

DATA AND INFORMATION FOR THE PERIOD I JANUARY 2009 TO 3T MARCH 2009
According to Decision 450728.04.2009 of the Capital Market Committee
ancial standing and the financial results of IALPIS S.A. We, therefore, recommend the reader, before proceeding to any kind of investment or other transaction with the company,
s.e.u, where all periodical financial statements under IFRS together with the Audit report of the external auditor (when necessary) are presented.

COMPANY DETAILS

The Group 31.03.2009 31.12.2008 1.615.707 1.524.905 The Company
31.03.2009 31.12.2008
1.181.608 1.155.66 The Group
1.1. - 31.03.2009 1.1. - 31.03.2008 1.1. The Company 03.2009 1.1. - 31.03.2008 ASSETS ASSETS
Property, plant and equipment
Investment properties
Intangible assets
Other non current assets
Inventories
Trade receivables
Other current assets perating activities rofits before taxes (continuous operation) rofits before taxes (discontinuous operation) luis less adjustments for: epreciation and amortization alin) / Loss from disposal of tangible assets rovisions 127 674.824 127 730.187 16.393 149.801 75.022 335.738 59 463,563 463.563 683.491 14.248 133.288 79.006 50.480 57.654 174.480 106.409 205.087 47.531 24.726 (322) (970) (4.035) (268) 13.721 16.205 (24) (2.351) (24) (31) 8.822 10.672 (1.801) 2.084 TOTAL ASSETS 2.881.820 2.832.174 2.605.743 2.454.889 EQUITY AND LIABILITIES /less changes in working capital 294,180 Share capital
Other equity items
Total owners' equity (a)
Non controlling interests (b)
Total equity (c) = (a) + (b)
Long term borrowings
Provisions' Other long term liabilities
Short-term borrowings
Other short term liabilities Decrease / (increase) of inventories Decrease / (increase) of trade receivables Decrease / (increase) of other receivales (25.480) (18.636) 21.438 (11.144) (38.171) (17.085) (3.435) (63.686) 13.270 1.548.665 700.000 51.325 125.282 179.296 1.176 3.333 1.543.001 1.528.323 664.843 49.001 135.430 77.292 ecrease) / Increase of trade liabilities (excluding borrowings) 1.497.968 79.523 (21.366) 46.653 (3.870) 75.968 23.029 (1.191) 1.753 ther short term liabilities on current liabilities available for sale (21.682) (1.089) 3.473 85.886 (3.405 (5.973) (1.135) 1.383.852 1.289.172 Total liabilities (d) 2.881.820 2.832.174 2.605.743 2.454.889 TOTAL EQUITY AND LIABILITIES (c)+(d) Investing activities (197.800) (1.733) 37 522 0 (41.637) (92.489) equisition of subsidiaries, related, joint ventures and other investments (117.788) (66.981 (70.969 STATEMENT OF COMPREHENSIVE INCOME (amounts in thousands €) urchase of tangible and intangible assets roceeds from disposal of tangible and intangible assets iterest received isposal of subsiadiaries (95.778) 955 719 0 (6) 1.802 89.910 1.879 1.1. - 31.03.2009 Discontinu - 31.03.2008 Continuing operations ans to subsidiaries (3.600) Proceeds from grants / Guarantees paid Investing cash flow form discontinued operation Net cash flows from investing activities (b) 4.022 (380) (3.519) (3.525) (2.679) 235.576 82.138 50.311 3.704 1.417 888 885 889 208.091 64.720 41.747 Revenue Gross profit/(loss) Profit before tax, financial and investing results (EBIT) Profit/(loss) before tax Profit/(loss) (a) (12) (211.966) (20.062) (152.302) (46.245) (202,464) 53.830 Financing activities Issue of share capital Proceeds from borrowings Payments of borrowings Principal repayments of finance lease obligations Dividents paid 40.377 33.789 36.852 31.109 38.154 31.350 39.03 32.23 35.157 (19.825) (639) 70.500 (43.609) (191) (157) 35.157 (10.148) 90.001 (2.679) 34.093 (304) reasury shares inancing activities from discontinued operation let cash flows from financing activities (c) Other comprehensive income (net of tax) (b)

Total comprehensive income (net of tax) (a) + (b) (2.679) 90.001 14.693 26.542 25.009 31.034 (85) mers of the parent n-controlling interests 33.979 (307) (2.679) 31.300 (307) at increase in cash and cash equivalents (a)+(b)+(c) (100.170) (111.387) (91.672) 13.758 121.305 163.168 Net profit per share - basic (in  $\epsilon$ ) Profit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA) Cash and cash equivalents at beginning of the period Cash and cash equivalents of discontinued operation Cash and cash equivalents at end of the period 0,0375 78.556 0,0346 75.824 0,0009 1.286 95.561 176.926 The Company .1. - 31.03.2009 1.1. - 31.03.2008 Continuing operations Continuino Total 93.417 93,417 (381) (473) (473) (369) 55.951 43.153 34.362 30.678 17.850 17.566 13.139 Gross profit/(loss)
Profit before tax, fin
Profit/(loss) before
Profit/(loss) (a) STATEMENT OF CHANGES IN EQUITY (amounts in thousands €) 30.711 30.341 (234) 12.90 The Group The Company
1.1. - 31.03.2009 1.1. - 31.03.2008 1.1. - 31.03.2009 1.1. - 31.03.2008 wners of the parent on-controlling interests Equity balance at the beginning of the period (1.1.2009 and 1.1.2008 respectively)
Total comprehensive income (net of tax) (continuing and discontinued operations)
Share capital increase/dicrease
Dividents
Purchase of treasury shares
Acquisition of subsidiaries (34) 13.106 (34 12.87 (234) 30.711 (369) 30.341 (9.999) (24.515) (24.515 (9.999) (66.027) 1.497.968 566 1.616.945 equity balance at the end of the period (31.03.2009 and 31.03.2008 respectively) 1.596.39 0,0338 59.832 (0,0004) 0,0334 59.832 0,0134 28.522 (0,0002) ADDITIONAL DATA AND INFORMATION

1. The companies included in the consolidated financial statements, together with their registered addresses, the consolidation method in the financial statements of the Company and their share of participation are analyzed in note 5 of the financial statements and the tax unaudited PYs of the companies are analyzed in note 14 of the financial statements.

2. During the first quarter of 2009, ALAPIS SA established and acquired the companies mentioned below.

During the first quarter of 2009, ALAPIS SA proceeded with the acquisition of the remaining 46% and 17% stake in SANTA PHARMA SA and PNG GEROLYMATOS MEDICAL SA respectively and 40% stake in ANDREAS CHIRISTOFOGLOU SA (allowing which ALAPIS SA now controls 100% of the some apain of 100% of the companies mentioned above.

On March 30, 2009, the Company proceeded with the acquisition of 100% of the company MEDIMEC SA and the signing of a preliminary agreement for the acquisition of the remaining 50,1% with the completion of approval by the Company EDIMEC SA (and the signing of a preliminary agreement for the acquisition of the remaining 50,1% with the completion of approval by the Company EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company are company and the Company and EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company and EDIMEC SA (and the signing statements of the Company EDIMEC SA (and the signing statements of the Company EDIMEC SA (and the signing statements of the Company EDIMEC SA (and the signing statements of the C ADDITIONAL DATA AND INFORMATION (continuation) or the agausition of the remaining 50,1% of MEDIMEC SA is still pending the approval of the Competition Commission.

The aforementioned companies were acquired during the current period and are consolidated at the financial statements of ALAPIS SA since their acquisition date.

The consolidated financial statements for the three month period ended March 31, 2009, do not include ALAPIS PHARIMALTH's was disposed on June 30,

000. During the forth quarter of 2008 the merger by absorption by the parent company of ALAPIS CROPSCIENCE SA, REVOLD SA, PHARMALEX SA and BIODOMUS SA was concluded a accordance with the provisions of article 78 of the CL 21902 and L 12977/2

1. Within the nine month period ended on 30.9.2008 the Purchase Price Allocation exercise for the acquired companies during the period 1.7.2007 to 30.9.2008 which are consolidated in the financial statements was finalized. Full analysis is quoted in the note of the current financial statements was finalized. Full analysis is quoted in the note 6 of the current financial statements was finalized. Full analysis is quoted in the note 6 of the current financial statements was finalized. Full analysis is quoted in the note 6 of the current financial statements was finalized. Full analysis is quoted in the note of the current financial statements was finally statements. The charge of the finalized finalized statements to the turnover, the profit after tax and non-controlling interest, the total comprehensive income after tax as well as to the total current financial statements. The finalized finalized finalized finalized statements to the turnover, the profit after tax and non-controlling interest, the total comprehensive income after tax as well as to the total current financial statements. GROUP 1.1-31.03.2008

Published Restat

208.091

33.314

32.858 Company have made no other problems of the contract of the Group and the Company is 2.950 and 424 respectively and for the Group and the Company respectively.

5. The number of employees at the eart of contract of the Group and the Company is 2.950 and 424 respectively and for the Group and the Company respectively.

5. Which the course of the lists quarter of 2003 the organic products sector controlled significant problems with gross and operating profit margin presenting steep decline. The decrease of profit margins and the losses that the sector presentes the first quarter of 2009 the organic products sector controlled significant problems with gross and operating profit margin presenting steep decline. The decrease of profit margins and the losses that the sector presentes the first quarter of 2009 the organic products and distributed in the sector presentes of the list quarter of 2009 the gross of significant problems are controlled to the sector presented in the list of the sector of the s Turnover Profit after tax and minority interest Total comprehensive income after tax 33.331\*

32.858
31.837

GROUP 1.1-31.03.2008

1.618.855

1.616.945

ontinuous operations in total.

GROUP

1.1-31.03.2009

(117)
(368)
(368) Shareholders' equity 12.The amounts and the nature of other comprehensive income after tax are analysed in the f COMPANY 1.1-31.03.2008 Other comprehensive income Currency translation differences Deferred tax directly attributable to equity 1.1-31.03.2009 80.958 19.638 173.137 39.026 365 0 55 Deferred tax directly attributable to equity

Other comprehensive income (later tax)

10 (34)

Other comprehensive income (later tax)

11 (117) (402)

12 (34)

Other comprehensive income (later tax)

13 (34)

Other comprehensive income (later tax)

14 (117) (402)

15 (34)

Other comprehensive income (later tax)

16 (34)

Other comprehensive income (later tax)

Other comprehensive income (later tax)

Other (la a) Income : b) Expenses: c) Receivables ol Receivables:
d) Liabilities
d) Labilities
d) Rewards to Managers and Members of the Board of Directors
d) S65
d) 365
d) S65
d) G
d)
d) Labilities
d) Receivables from Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Members of the Weighted Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d) Labilities to Managers and Members of the Board of Directors
d